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Summary
Background Non-typhoidal salmonella invasive disease is a major cause of global morbidity and mortality. 
Malnourished children, those with recent malaria or sickle-cell anaemia, and adults with HIV infection are at 
particularly high risk of disease. We sought to estimate the burden of disease attributable to non-typhoidal salmonella 
invasive disease for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017.
Methods We did a systematic review of scientific databases and grey literature, and estimated non-typhoidal salmonella 
invasive disease incidence and mortality for the years 1990 to 2017, by age, sex, and geographical location using 
DisMod-MR, a Bayesian meta-regression tool. We estimated case fatality by age, HIV status, and sociodemographic 
development. We also calculated the HIV-attributable fraction and estimated health gap metrics, including disability-
adjusted life-years (DALYs).
Findings We estimated that 535 000 (95% uncertainty interval 409 000–705 000) cases of non-typhoidal salmonella 
invasive disease occurred in 2017, with the highest incidence in sub-Saharan Africa (34·5 [26·6–45·0] cases per 
100 000 person-years) and in children younger than 5 years (34·3 [23·2–54·7] cases per 100 000 person-years). 
77 500 (46 400–123 000) deaths were estimated in 2017, of which 18 400 (12 000–27 700) were attributable to HIV. The 
remaining 59 100 (33 300–98 100) deaths not attributable to HIV accounted for 4·26 million (2·38–7·38) DALYs in 
2017. Mean all-age case fatality was 14·5% (9·2–21·1), with higher estimates among children younger than 5 years 
(13·5% [8·4–19·8]) and elderly people (51·2% [30·2–72·9] among those aged ≥70 years), people with HIV infection 
(41·8% [30·0–54·0]), and in areas of low sociodemographic development (eg, 15·8% [10·0–22·9] in sub-Saharan 
Africa).
Interpretation We present the first global estimates of non-typhoidal salmonella invasive disease that have been 
produced as part of GBD 2017. Given the high disease burden, particularly in children, elderly people, and people 
with HIV infection, investigating the sources and transmission pathways of non-typhoidal salmonella invasive 
disease is crucial to implement effective preventive and control measures.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Non-typhoidal salmonella infections most commonly 
result in self-limiting diarrhoeal illness with low case 
fatality. The Global Burden of Diseases, Injuries, and 
Risk Factors Study (GBD) 2017 estimated that salmo-
nella enterocolitis resulted in 95·1 million cases 
(95% uncertainty interval [UI] 41·6–184·8), 50 771 deaths 
(2824–129 736), and 3·10 million DALYs (0·39–7·39) in 
2017.1–3 In addition to diarrhoeal disease, non-typhoidal 
salmonella infections can invade normally sterile 
sites, resulting in bacteraemia, meningitis, and other 
focal infections. Referred to as invasive non-typhoidal 
salmonella disease, these infections are not typically 
associated with diarrhoea but present as non-specific 
febrile illnesses with symptoms that are clinically 
indistinguishable from other febrile illnesses, and with 
higher case fatality than is seen with non-invasive 
infection.4 Malnourished infants, elderly people, and 
individuals with sickle-cell disease, HIV, and acute or 
recent malaria are at particular risk.5–10
Invasive disease is seen most commonly in sub-
Saharan Africa, where certain non-typhoidal salmonella 
serovars and sequence types are endemic, including 
Salmonella enterica serovars Typhimurium sequence type 
(ST) 313, Enteritidis ST 11, Dublin, and Isangi.8,11–13 A 
recently emerged highly invasive S Typhimurium strain, 
ST 313, has caused large epidemics of non-typhoidal 
salmonella bacteraemia showing resistance to multiple 
antimicrobial agents, including those recommended 
as first-line treatment.12 Similarly, a new variant of 
multidrug-resistant S Typhimurium, ST 34, has been 
associated with invasive disease in immuno compromised 
patients in Vietnam.14 Antimicrobial-resistant infections 
are associated with poorer clinical outcomes and higher 
case fatality.15 Studies evaluating the proportion of total 
isolates that are invasive, referred to as the invasiveness 
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index, have identified Salmonella enterica serovars 
Dublin, Choleraesuis, Heidelberg, and Virchow as the 
most invasive.10,16,17 Conversely, Salmonella enterica serovar 
Newport has been associated with a lower risk of 
bacteraemia than S Typhimurium.16
Two previous studies have published estimates of the 
global burden of non-typhoidal salmonella invasive 
disease. Ao and colleagues5 used an HIV and malaria 
burden matrix extrapolated to countries without data and 
estimated that 3·4 million cases of non-typhoidal 
salmonella invasive disease and 681 316 deaths from non-
typhoidal salmonella invasive disease occurred in 2010. 
WHO estimated that 596 824 cases of non-typhoidal 
salmonella invasive disease occurred in 2010, resulting 
in 63 312 deaths—considerably lower estimates than in 
the previous study.5 Both estimates were based on a small 
number of studies primarily from sub-Saharan Africa, 
and neither study estimated disease trends or modelled 
case fatality.
We present estimates of the non-typhoidal salmonella 
invasive disease burden from GBD 2017. GBD 2017 is the 
first iteration of GBD to include non-typhoidal salmonella 
invasive disease in its cause list. An updated and broadly 
scoped systematic review and improved estimation 
methods have allowed us to address some of the 
shortcomings of previously published estimates and 
provide a more complete picture of the non-typhoidal 
salmonella invasive disease burden. We present estimates 
of non-typhoidal salmonella invasive disease incidence 
and mortality by year, age, sex, and location. Additionally, 
we modelled non-typhoidal salmonella invasive disease 
case fatality and the proportion of cases attributable to 
HIV, and estimated health gap metrics, including years of 
life lost (YLLs) to premature mortality, years lived 
with disability (YLDs), and disability-adjusted life-years 
(DALYs).
Methods
Systematic review
We searched scientific databases, including PubMed, 
Web of Science, and Scopus, grey literature databases 
including Open Grey and Dart Europe, and other grey 
literature sources including websites of WHO, the 
European Food and Safety Authority, Health Canada, and 
the US Centers for Disease Control and Prevention for 
studies published between Jan 1, 1980, and July 19, 2017, 
that reported data on non-typhoidal salmonella invasive 
disease incidence, case fatality, or HIV co-infection. We 
Research in context
Evidence before this study
We searched PubMed, Web of Science, Scopus, and the grey 
literature using the search terms “(Salmonella OR salmonellosis) 
AND (nontyphoidal) AND (bacteraemia OR septicaemia OR 
bloodstream OR invasive) AND (incidence OR prevalence OR 
burden OR proportion OR fatality OR risk)” between 
Jan 1, 1980, and July 19, 2017, with no language restrictions. 
We identified two studies reporting the global non-typhoidal 
salmonella invasive disease burden. Both studies estimated the 
incidence of non-typhoidal salmonella invasive disease based 
on data from ten studies, of which seven were done in Africa. 
One estimated 597 000 cases and 63 300 deaths from 
non-typhoidal salmonella invasive disease in 2010; the other 
estimated 3·4 million cases and 681 000 deaths per year. No 
study has, to the best of our knowledge, estimated disease 
trends, modelled case fatality, or calculated the attributable 
fraction of risk factors, including co-infection with HIV.
Added value of this study
We present estimates of incidence, mortality, and case fatality 
for non-typhoidal salmonella invasive disease by year, age, sex, 
and country using data from 66 studies. We also calculated the 
HIV-attributable fraction and health gap metrics, including 
years of life lost (YLLs) to premature mortality, years lived with 
disability (YLDs), and disability-adjusted life-years (DALYs), 
as part of the Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2017. Using a broadly scoped systematic 
review allowed us to identify many studies that were not 
included in the previous two estimates of non-typhoidal 
salmonella invasive disease burden, and using the DisMod 
modelling tool allowed us to integrate data with GBD and 
include other significant covariates in our model. 
This systematic analysis is, to the best of our knowledge, the 
first study presenting estimates of non-typhoidal salmonella 
invasive disease temporal trends, HIV-attributable fraction, 
and case fatality derived analytically at country, regional, 
and global levels. Finally, our estimates allow non-typhoidal 
salmonella invasive disease to be placed within the general 
context of the global burden of other diseases as presented in 
GBD 2017.
Implications of all the available evidence
Although the available evidence on non-typhoidal salmonella 
invasive disease is scarce, particularly in Latin America, we 
identified a high disease burden of non-typhoidal salmonella 
invasive disease in children, elderly people, and people with 
HIV infection, and in areas of low socioeconomic 
development. Non-typhoidal salmonella invasive disease is 
not as common as salmonella enterocolitis, but it results in 
similar numbers of deaths and DALYs. Therefore, investigating 
sources and transmission pathways of non-typhoidal 
salmonella invasive disease is crucial to implement effective 
preventive and control measures and conduct more studies 
from other geographical locations. Lastly, additional studies 
on other risk factors, including malaria, acute malnutrition, 
and sickle cell disease, are needed to calculate the attributable 
fraction of these risk factors to the non-typhoidal salmonella 
invasive disease burden.
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defined a case of non-typhoidal salmonella invasive 
disease as culture-confirmed non-typhoidal salmonella 
infection of a normally sterile site (eg, blood). We 
excluded editorial letters, case studies, and reviews. No 
language restrictions were applied. Studies were 
independently screened by two authors (AP and KS), 
with any discrepancies discussed with a third author 
(JDS). Backward citation screening of eligible studies 
was also done. Search strategies and inclusion and 
exclusion criteria are detailed in the appendix (pp 3–6).
The review protocol is available in PROSPERO, 
CRD42017077141.18 The complete methodology is 
presented in the appendix (pp 3–6).
Incidence estimation
We used data from cohort studies, clinical trials, and 
case notification systems to estimate non-typhoidal 
salmonella invasive disease incidence. Clinic-based and 
hospital-based studies often applied adjustments to 
correct for incomplete case capture. We extracted 
estimates that made adjustments for the catchment 
population and incomplete enrolment of eligible 
patients. Given the severity of non-typhoidal salmonella 
invasive disease, we did not include adjustments for 
health-seeking behaviour, which are generally based on 
responses in household surveys to questions about 
health-seeking behaviour for less severe, uncomplicated 
fever.
We modelled the incidence of non-typhoidal 
salmonella invasive disease by location, year, age, and 
sex by use of DisMod-MR, a Bayesian meta-regression 
tool that has been described elsewhere.3 Briefly, DisMod 
is a non-linear mixed-effects model that uses a Bayesian 
cascading geographical hierarchy in which all data are 
pooled to estimate a global fit, which then acts as a 
prior for each of the seven GBD super-regions 
(appendix p 2). The model includes hierarchical nested 
random effects at every level of the geographical 
hierarchy, and fixed effects for covariates. DisMod uses 
age integration to allow use of data with non-
standardised age categorisation schemes and estimate 
location-specific age patterns.
We included three predictive covariates in our 
incidence model: HIV mortality rate, malaria incidence 
adjusted for antimalarial coverage and drug effectiveness, 
and an index of unsafe water exposure. All covariates 
were derived from GBD estimates.1,19,20 HIV and malaria 
were included as they are known risk factors for non-
typhoidal salmonella invasive disease and have been 
previously shown to be strong predictors of non-typhoidal 
salmonella invasive disease incidence,5 and we included 
exposure to unsafe water supply types as a proxy for 
potential exposure to the underlying pathogen. We 
quantified unsafe water exposure using the summary 
exposure value, a metric of the risk-weighted prevalence 
of exposure to unimproved water, weighted by the type of 
water supply.19
Case fatality
We estimated case fatality by age, HIV status, and 
socioeconomic development. Not all studies reported 
case fatality separately for non-typhoidal salmonella 
invasive disease with and without HIV infection. Where 
studies reported case fatality separately for HIV status, 
we included those as separate data points for which we 
assigned each point an HIV prevalence of 1 or 0. For 
studies that reported overall case fatality, we included a 
single case fatality data point with the HIV prevalence 
corresponding to the reported prevalence of HIV among 
non-typhoidal salmonella invasive disease cases in that 
study. We quantified development using the Socio-
demographic Index (SDI), a measure of development 
level based on the total fertility rate among women 
younger than 25 years of age, mean education for those 
aged 15 years and older, and lag-distributed income 
per capita.19 Finally, we used a generalised additive model 
with linear terms on HIV prevalence and SDI, and 
P-splines on age to allow for a flexible, non-linear age 
pattern.
HIV attribution
For each location, year, age, and sex, we estimated the 
proportion of cases attributable to HIV based on the 
relative risk (RR) of non-typhoidal salmonella invasive 
disease, comparing those with HIV to those without 
HIV. We used negative binomial regression to model 
RRs as a function of age and the summary exposure 
value for diarrhoea risk:
The diarrhoea summary exposure value is an index of 
exposure to risk factors for diarrhoea that is estimated in 
the GBD risk factor analysis and has been detailed 
elsewhere.19 These variables were included as we expect 
them to be strong predictors of the underlying risk of non-
typhoidal salmonella invasive disease in the absence of 
HIV, and should thus strongly predict the baseline risk of 
non-typhoidal salmonella invasive disease (ie, the risk 
among the unexposed). We estimated the proportion of 
non-typhoidal salmonella invasive disease cases attributable 
to HIV as the population attributable fraction (PAF), 
calculated as
where Phiv is the prevalence of HIV in the population. The 
PAF does not equal the prevalence of HIV among those 
with non-typhoidal salmonella invasive disease; rather, it 
equals the proportion of non-typhoidal salmonella invasive 
disease cases that are attributable to HIV infection. This 
approach assumes that some portion of non-typhoidal 
salmonella invasive disease cases among those with HIV 
were not a direct result of the HIV infection.
See Online for appendix
In(RRHIV)=∝ + β1 × ln(age) + β2 × ln(SEVdiarrhoea)
Phiv × (RR – 1) 
Phiv × (RR – 1) + 1
PAF =
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We estimated the incidence of non-typhoidal sal- 
monella invasive disease attributable to HIV for each 
location, year, age, and sex as the product of the total 
incidence of non-typhoidal salmonella invasive disease 
and the HIV PAF, and the incidence of non-typhoidal 
salmonella invasive disease not attributable to HIV for 
each location, year, age, and sex as the product of the total 
incidence of non-typhoidal salmonella invasive disease 
and one minus the HIV PAF.
Mortality estimation
We estimated HIV-attributable non-typhoidal salmonella 
invasive disease mortality rates as the product of the 
HIV-attributable non-typhoidal salmonella invasive 
disease incidence and the corresponding estimate of 
non-typhoidal salmonella invasive disease case fatality 
among those living with HIV, and non-HIV-attributable 
non-typhoidal salmonella invasive disease mortality 
rates as the product of the non-HIV-attributable non-
typhoidal salmonella invasive disease incidence and the 
corres ponding estimate of non-typhoidal salmonella 
invasive disease case fatality among those living without 
HIV (appendix p 8).
A fundamental principle of the GBD approach is that 
the list of causes of death is considered to be mutually 
exclusive and collectively exhaustive such that each 
death must be assigned to a single cause and the sum of 
all cause-specific mortality estimates must equal all-
cause mortality within each age, sex, year, and location. 
Where a death might be considered to result from 
multiple causes, we assigned the death to the underlying 
cause. We therefore considered the underlying cause of 
death to be HIV for all non-typhoidal salmonella invasive 
disease deaths that were attributable to HIV. Although 
we estimated total non-typhoidal salmonella invasive 
disease mortality, the final GBD mortality estimates 
include only deaths from non-typhoidal salmonella 
invasive disease not attributable to HIV. Finally, we 
imposed consistency between cause-specific and all-
cause mortality estimates across all causes in GBD 
through CoDCorrect, a process in which we rescaled 
cause-specific mortality estimates to fit the all-cause 
mortality envelope.1
Health gap metric estimation
We estimated three health gap metrics: YLLs, YLDs, and 
DALYs. The number of YLLs resulting from a given death 
is equal to the life expectancy at the age of death, based 
on a reference life table, and the total number of YLLs for 
a given location and year equal the sum of all age-specific 
YLLs. YLDs are calculated as the product of prevalence 
and a disability weight that quantifies the severity of the 
outcome. DALYs are calculated as the sum of YLLs 
and YLDs.
We calculated prevalence as the product of incidence 
and duration, doing all calculations at the draw level to 
incorporate uncertainty in both incidence and duration 
estimates. Given the broad but almost universally 
severe clinical presentations of non-typhoidal salmonella 
invasive disease, we applied the health state “severe acute 
infectious disease episode” to all cases of non-typhoidal 
salmonella invasive disease, with a corresponding 
disability weight of 0·133 (95% UI 0·088–0·190). We 
assumed that 95% of causes would result in symptoms 
lasting between 7 and 21 days.21 We estimated YLDs as the 
product of this disability weight and prevalence. Finally, 
we adjusted YLDs through a comorbidity cor rection to 
ensure that comorbidities cannot result in an aggregate 
disability weight greater than one (equivalent to death).
Data management was done with Stata, version 13, and 
R, version 3.4.3. We estimated RRs for HIV using Stata 
version 13, and case fatality using the mgcv package in 
R, version 1.8.23.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
Cases (thousands) Incidence 
(per 100 000)
Proportion of cases 
attributable to HIV
Year
1990 342·0 (264·8 to 451·2) 5·9 (4·6 to 7·7) 5·2 (2·6 to 8·5)
1995 410·5 (319·7 to 535·9) 6·8 (5·3 to 8·8) 8·9 (4·8 to 14·2)
2000 521·2 (410·4 to 669·4) 8·3 (6·6 to 10·7) 11·0 (6·0 to 17·5)
2005 690·7 (552·2 to 873·6) 10·7 (8·5 to 13·6) 10·4 (5·5 to 16·9)
2010 622·0 (490·1 to 800·0) 9·2 (7·3 to 12·0) 8·5 (4·3 to 14·0)
2017 534·6 (409·0 to 705·0) 7·5 (5·7 to 10·0) 8·2 (4·4 to 13·2)
GBD super-region
Southeast Asia, east Asia, 
and Oceania
21·5 (15·7 to 28·3) 1·2 (0·9 to 1·6) 2·0 (1·1 to 3·3)
Central Europe, eastern 
Europe, and central Asia
4·8 (3·6 to 6·1) 1·3 (1·0 to 1·7) 5·3 (3·2 to 8·2)
High-income 10·9 (8·1 to 13·7) 1·1 (0·8 to 1·4) 19·1 (9·0 to 32·6)
Latin America and 
Caribbean
11·2 (8·4 to 14·4) 2·0 (1·5 to 2·6) 5·5 (3·1 to 8·9)
North Africa and Middle 
East
15·8 (12·3 to 20·3) 2·5 (2·0 to 3·2) 0·5 (0·2 to 0·9)
South Asia 48·9 (35·8 to 64·6) 2·7 (2·0 to 3·5) 0·9 (0·5 to 1·7)
Sub-Saharan Africa 421·6 (316·0 to 574·1) 34·5 (26·6 to 45·0) 9·5 (5·0 to 15·7)
Age group
<5 years 233·4 (158·2 to 372·4) 34·3 (23·2 to 54·7) 0·5 (0·0 to 1·3)
5–14 years 120·8 (68·7 to 183·2) 9·3 (5·3 to 14·1) 1·6 (0·7 to 3·1)
15–49 years 146·9 (107·4 to 201·2) 3·8 (2·7 to 5·1) 22·3 (13·7 to 32·7)
50–69 years 26·8 (16·6 to 39·6) 2·0 (1·3 to 3·0) 25·4 (13·9 to 38·4)
≥70 years 6·6 (4·5 to 9·8) 1·5 (1·0 to 2·3) 15·5 (7·2 to 26·6)
Sex
Male 278·2 (212·8 to 370·3) 7·7 (5·8 to 10·3) 7·6 (4·0 to 12·4)
Female 256·4 (196·1 to 340·8) 7·4 (5·6 to 9·9) 8·9 (4·9 to 14·3)
95% uncertainty intervals are included in parentheses. Year-specific, age-specific, and sex-specific estimates are 
global estimates for 2017. Rates are age standardised, except for age-specific estimates. GBD=Global Burden of 
Disease.
Table 1: Cases and incidence of non-typhoidal salmonella invasive disease, and the proportion of cases 
attributable to HIV, by year, super-region, age, and sex
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writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
After removing 2086 duplicate records, we screened 
2480 publications by title and 588 by abstract, and 
408 underwent full-text screening. 66 studies met our 
inclusion criteria: 35 reported data on incidence, 35 on 
case fatality rate, and six on co-infections with HIV 
(appendix pp 7, 52–56).
An estimated 342 000 (95% UI 265 000–451 000) cases of 
non-typhoidal salmonella invasive disease occurred 
globally in 1990, increasing to 691 000 (552 000–874 000) 
cases in 2005 and declining to 535 000 (409 000–705 000) 
cases in 2017 (table 1). Age-standardised incidence showed 
a similar trend, with 5·9 (4·6–7·7) cases per 100 000 person-
years in 1990, increasing to 10·7 (8·5–13·6) cases per 
100 000 person-years in 2005 and decreasing to 
7·5 (5·7–10·0) cases per 100 000 person-years in 2017. For 
all years, we observed the largest numbers of cases and 
highest incidence in sub-Saharan Africa (figure 1; 
appendix pp 15, 24): in 2017 the age-standardised incidence 
of non-typhoidal salmonella invasive disease in 
sub-Saharan Africa was 34·5 (26·6–45·0) cases per 
100 000 person-years, and this super-region accounted for 
78·8% (74·6–82·9) of all cases globally.
Globally, we observed the highest incidence of non-
typhoidal salmonella invasive disease among children 
younger than 5 years, with substantially declining 
incidence between ages 5 years and 15 years, followed by 
low incidence among those aged 15 years and older, and 
slight increases around age 35 years and with increasing 
age among those older than 85 years (appendix p 11). 
Slightly different patterns emerged within different 
epidemiological contexts. In the high-income super-
region, the age pattern was U-shaped, with the highest 
incidence among young and elderly people (figure 2A); 
in low-income and middle-income regions outside of 
sub-Saharan Africa, we saw the highest rates among 
children, with lower rates throughout adulthood 
(figure 2B); and in sub-Saharan Africa we saw the highest 
rates among children, but also an approximately two-fold 
to three-fold increase between age 15–19 years and age 
35–49 years, reflecting the effect of the region’s high HIV 
prevalence on the risk of non-typhoidal salmonella 
invasive disease (figure 2C). Incidence was not signi- 
ficantly different for males and females; the 95% UIs for 
each sex include the point estimate for the other sex 
(table 1).
<1
1·0–1·9
2·0–4·9
5·0–19·9
20–59·9
>60
Incidence (per 100 000)
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Figure 1: Non-typhoidal salmonella invasive disease incidence rates (per 100 000), by country, in 2017
Locations filled in white are those for which the Global Burden of Disease Study (GBD) does not produce estimates. The inset maps detail smaller locations. ATG=Antigua and Barbuda. VCT=Saint 
Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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Estimates of the RR of non-typhoidal salmonella 
invasive disease associated with HIV infection were 
higher with older age and with lower levels of diarrhoea 
risk exposure (appendix p 13). In 2017, RR estimates 
ranged from 2·89 (95% UI 1·14–7·32) among those 
younger than 1 year of age in sub-Saharan Africa to 
232·64 (76·81–704·57) among those aged 90–95 years in 
the high-income super-region. Globally, we estimated 
that 5·2% (2·6–8·5) of non-typhoidal salmonella invasive 
disease cases were attributable to HIV in 1990, increasing 
to 11·0% (6·0–17·5) in 2000, and declining to 8·2% 
(4·4–13·2) in 2017 (table 1). Our model suggests that the 
proportion of cases attri butable to HIV was highest in 
countries with higher HIV risk and lower diarrhoea risk 
(figure 3).
Mean all-age case fatality was 14·5% (95% UI 
9·2–21·1) in 2017, with higher estimates among 
children younger than 5 years (13·5% [8·4–19·8]) and 
elderly people (51·2% [30·2–72·9] among those aged 
≥70 years), people with HIV infection (41·8% 
[30·0–54·0]), and in areas of low sociodemographic 
development (eg, 15·8% [10·0–22·9] in sub-Saharan 
Africa; appendix pp 12, 13). In 2017, mean case fatality 
among those living with HIV was 41·8% (30·0–54·0), 
compared with 12·0% (7·3–18·0) among those without 
HIV. At the global level, estimates of non-typhoidal 
salmonella invasive disease case fatality in 2017 ranged 
from a low of 8·8% (5·3–13·4) among those aged 
5–14 years without HIV, to a high of 75·7% (58·0–88·1) 
among those aged 70 years and older with HIV 
(appendix p 12).
We estimated that 51 800 (95% UI 29 800–83 900) deaths 
from non-typhoidal salmonella invasive disease occurred 
globally in 1990, increasing to 108 000 (66 600–164 000) 
in 2005, and declining to 77 500 (46 400–123 000) in 
2017 (table 2). Age-standardised mortality rates showed 
a similar trend, with 9·4 (5·4–15·0) deaths per 
100 000 person-years in 1990, increasing to 
16·8 (10·4–25·5) per 100 000 person-years in 2005, and 
decreasing to 10·7 (6·4–17·0) per 100 000 person-years 
in 2017. Of these, 17·9% (12·3–23·9) were attributable to 
HIV in 1990, as were 31·1% (23·3–40·1) in 2005, and 
24·3% (16·9–32·9) in 2017. After removing deaths from 
non-typhoidal salmonella invasive disease for which HIV 
was considered the underlying cause of death, final GBD 
estimates for non-typhoidal salmonella invasive disease 
mortality were 42 800 (23 600–72 700) deaths in 1990, 
74 800 (43 300–120 000) deaths in 2005, and 59 100 
(33 300–98 100) deaths in 2017. The spatial distribution of 
mortality rates is similar to that for incidence rates 
(figure 4).
We estimated that non-typhoidal salmonella invasive 
disease was responsible for 1750 (95% UI 1000–2740) 
YLDs in 1990, 3490 (2060–5440) YLDs in 2005, and 
2730 (1550–4290) YLDs in 2017. On average, each death 
from non-typhoidal salmonella invasive disease resulted 
in 72·0 (67·4–76·3) YLLs, resulting in 2·99 million 
(1·63–5·22) YLLs due to non-typhoidal salmonella 
invasive disease in 1990, 5·33 million (3·11–8·72) in 
2005, and 4·26 million (2·38–7·38) in 2017. Non-
typhoidal salmonella invasive disease was responsible for 
3·00 million (1·63–5·22) DALYs in 1990, 5·33 million 
(3·11–8·73) in 2005, and 4·26 million (2·38–7·38) in 
2017 (table 3).
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Discussion
We estimate that 535 000 (95% UI 409 000–705 000) cases 
of non-typhoidal salmonella invasive disease occurred in 
2017, which caused 77 500 (46 400–123 000) deaths 
(including those for which non-typhoidal salmonella 
invasive disease was attributable to HIV) and 
4·26 million (2·38–7·38) DALYs. In the same year, an 
estimated 14·3 million (12·5–16·3) cases of typhoid and 
paratyphoid fever occurred, which led to 136 000 
(76 900–219 000) deaths and 9·8 million (5·6–15·8) 
DALYs.21 So, although typhoid and paratyphoid fever 
were responsible for more than 25 times as many cases 
as non-typhoidal salmonella invasive disease, the greater 
severity and case fatality of non-typhoidal salmonella 
invasive disease resulted in almost half as many deaths 
and DALYs as did typhoid and paratyphoid fever. 
Similarly, an estimated 95·1 million (41·6–184·8) cases 
of salmonella enterocolitis occurred in 2017, which led to 
50 800 (2820–130 000) deaths and 3·10 million 
(0·39–7·39) DALYs.1–3 Although salmonella enterocolitis 
occurs far more commonly than does non-typhoidal 
salmonella invasive disease, the number of deaths and 
DALYs caused by each disease is similar.
Two previous studies reported non-typhoidal salmo- 
nella invasive disease burden estimates, and both 
produced estimates for the year 2010.5,22 Compared with 
our estimates for the same year, those published by WHO 
were slightly, but not substantially, lower. Whereas WHO 
estimated that non-typhoidal salmonella invasive disease 
caused 597 000 illnesses, 63 300 (95% UI 39 000–94 200) 
deaths, and 3·90 million (2·40–5·79) DALYs in 2010, 
we estimated 622 000 (490 000–800 000) cases, 67 600 
(39 200–110 000) deaths, and 4·85 million (2·75–8·12) 
DALYs.21 Our estimates for 2010 are, however, significantly 
lower than those by Ao and colleagues, of 3·4 million 
non-typhoidal salmonella invasive disease cases and 
681 000 deaths for the same year.5 As previously reported, 
the highest number of non-typhoidal salmonella invasive 
disease cases occurred in Africa and among children 
younger than 5 years.5,21 Ao and colleagues estimated the 
case fatality rate to be 20%.5 The WHO study assumed 
that the case fatality rate for non-typhoidal salmonella 
invasive disease in individuals not infected with HIV 
ranged from 3·9% to 20%, with higher values in countries 
with higher overall child and adult mortality rates.22 In 
our study, mean all-age case fatality was 14·5% in 2017, 
with higher estimates among children, elderly people, 
and those with HIV, and in low SDI settings.
Our comprehensive systematic review allowed us to 
identify studies not included in previous estimates.5,22 We 
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present the first non-typhoidal salmonella invasive 
disease burden estimates to include temporal trends and 
HIV-attributable fraction, and the first analytically derived 
estimates of non-typhoidal salmonella invasive disease 
case fatality. The DisMod modelling tool allowed us to use 
data with disparate age classification schemes and 
Deaths and mortality rates in 
people without HIV infection
Deaths and mortality rates in 
people with HIV infection
Total deaths and mortality rates Proportion of 
cases 
attributable 
to HIV (%)
Deaths 
(thousands)
Mortality rate 
(per million)
Deaths 
(thousands)
Mortality rate 
(per million)
Deaths 
(thousands)
Mortality rate 
(per million)
Year
1990 42·78 
(23·62 to 72·70)
7·60 
(4·27 to 12·55)
9·02 
(5·96 to 13·22)
1·78 
(1·18 to 2·59)
51·81 
(29·75 to 83·92)
9·38 
(5·44 to 15·02)
17·9% 
(12·3 to 23·9)
1995 48·58 
(27·01 to 80·99)
8·27 
(4·64 to 13·63)
17·87 
(12·17 to 25·81)
3·19 
(2·17 to 4·59)
66·45 
(39·59 to 104·91)
11·46 
(6·91 to 17·83)
27·5% 
(20·1 to 35·5)
2000 59·06 
(32·68 to 97·53)
9·71 
(5·38 to 15·94)
27·48 
(18·65 to 40·13)
4·48 
(3·05 to 6·49)
86·54 
(52·48 to 133·64)
14·19 
(8·63 to 21·85)
32·3% 
(24·4 to 41·3)
2005 74·81 
(43·33 to 120·08)
11·81 
(6·87 to 19·00)
33·13 
(21·99 to 49·05)
4·98 
(3·33 to 7·35)
107·93 
(66·61 to 163·87)
16·79 
(10·36 to 25·49)
31·1% 
(23·3 to 40·1)
2010 67·56 
(39·19 to 110·02)
10·14 
(5·84 to 16·53)
23·36 
(15·30 to 35·10)
3·25 
(2·14 to 4·88)
90·92 
(55·54 to 140·01)
13·39 
(8·21 to 20·70)
26·2% 
(19·1 to 34·2)
2017 59·07 
(33·32 to 98·06)
8·37 
(4·73 to 13·99)
18·40 
(12·01 to 27·68)
2·31 
(1·50 to 3·45)
77·47 
(46·36 to 122·80)
10·68 
(6·42 to 17·02)
24·3% 
(16·9 to 32·9)
GBD super-region
Southeast Asia, 
east Asia, and 
Oceania
1·60 
(0·86 to 2·68)
0·83 
(0·45 to 1·38)
0·16 
(0·09 to 0·24)
0·06 
(0·04 to 0·10)
1·75 
(0·96 to 2·88)
0·89 
(0·48 to 1·47)
9·2% 
(6·5 to 12·0)
Central Europe, 
eastern Europe, 
and central Asia
0·38 
(0·20 to 0·66)
0·89 
(0·47 to 1·53)
0·06 
(0·03 to 0·11)
0·13 
(0·07 to 0·22)
0·45 
(0·24 to 0·76)
1·02 
(0·54 to 1·76)
14·4% 
(9·7 to 19·7)
High-income 0·70 
(0·32 to 1·29)
0·50 
(0·24 to 0·89)
0·68 
(0·38 to 1·03)
0·41 
(0·22 to 0·63)
1·38 
(0·72 to 2·25)
0·91 
(0·49 to 1·51)
50·0% 
(39·4 to 59·0)
Latin America and 
Caribbean
0·81 
(0·45 to 1·34)
1·46 
(0·81 to 2·40)
0·23 
(0·14 to 0·34)
0·38 
(0·22 to 0·56)
1·04 
(0·59 to 1·68)
1·84 
(1·04 to 2·99)
22·3% 
(16·9 to 28·3)
North Africa and 
Middle East
1·63 
(0·91 to 2·66)
2·76 
(1·56 to 4·45)
0·03 
(0·01 to 0·05)
0·05 
(0·03 to 0·08)
1·66 
(0·93 to 2·70)
2·81 
(1·60 to 4·52)
1·7% 
(1·0 to 2·7)
South Asia 4·50 
(2·47 to 7·45)
2·60 
(1·43 to 4·25)
0·17 
(0·10 to 0·26)
0·10 
(0·06 to 0·15)
4·67 
(2·55 to 7·72)
2·69 
(1·48 to 4·42)
3·6% 
(2·4 to 5·1)
Sub-Saharan Africa 49·44 
(27·57 to 83·50)
43·11 
(24·33 to 70·34)
17·08 
(11·05 to 25·73)
23·66 
(15·48 to 35·37)
66·52 
(40·13 to 105·50)
66·78 
(41·72 to 99·09)
26·2% 
(18·0 to 35·7)
Age group
<5 years 31·20 
(16·20 to 56·59)
45·84 
(23·80 to 83·14)
0·43 
(0·21 to 0·85)
0·64 
(0·31 to 1·24)
31·63 
(16·40 to 57·49)
46·48 
(24·09 to 84·47)
1·4% 
(0·8 to 2·3)
5–14 years 10·40 
(5·16 to 18·72)
8·02 
(3·98 to 14·43)
0·76 
(0·36 to 1·36)
0·58 
(0·27 to 1·05)
11·16 
(5·53 to 19·90)
8·60 
(4·27 to 15·34)
6·9% 
(5·0 to 9·2)
15–49 years 10·03 
(4·73 to 18·02)
2·56 
(1·21 to 4·61)
12·49 
(7·57 to 19·75)
3·19 
(1·93 to 5·05)
22·52 
(12·80 to 36·79)
5·76 
(3·27 to 9·41)
56·0% 
(45·7 to 65·7)
50–69 years 4·92 
(2·52 to 8·18)
3·73 
(1·91 to 6·21)
3·84 
(2·31 to 5·91)
2·92 
(1·76 to 4·48)
8·76 
(4·91 to 13·77)
6·65 
(3·73 to 10·45)
44·3% 
(35·8 to 53·0)
≥70 years 2·52 
(1·15 to 4·47)
5·82 
(2·66 to 10·33)
0·88 
(0·54 to 1·39)
2·03 
(1·26 to 3·22)
3·40 
(1·72 to 5·74)
7·85 
(3·98 to 13·26)
26·7% 
(19·4 to 37·0)
Sex
Male 30·97 
(17·36 to 51·91)
8·62 
(4·81 to 14·48)
9·00 
(5·83 to 13·50)
2·27 
(1·47 to 3·37)
39·97 
(23·63 to 64·21)
10·88 
(6·43 to 17·56)
23·0% 
(15·8 to 31·6)
Female 28·10 
(16·01 to 46·61)
8·14 
(4·62 to 13·65)
9·40 
(6·09 to 14·32)
2·36 
(1·53 to 3·60)
37·50 
(22·89 to 58·79)
10·50 
(6·34 to 16·54)
25·6% 
(18·0 to 34·4)
95% uncertainty intervals are included in parentheses. Year-specific, age-specific, and sex-specific estimates are global estimates for 2017. Rates are age standardised, except 
for age-specific estimates. GBD=Global Burden of Disease.
Table 2: Deaths and mortality rates for non-typhoidal salmonella invasive disease, among those living with and without HIV, and the total population, 
by year, super-region, age, and sex
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estimate location-year-specific age patterns, and it allowed 
us to use information from predictive covariates while 
ensuring that our estimates maintained a strong spatial 
structure. Using posterior simulation allowed us to 
propagate uncertainty from all components through the 
modelling chain. Finally, integrating our model within 
the larger GBD framework allowed us to correct our 
mortality estimates to account for other causes of death, 
through CoDCorrect, and to adjust non-fatal burden for 
comorbidities, through comorbidity correction.
Still, data on non-typhoidal salmonella invasive disease 
remain scarce, and we identified few studies reporting 
incidence from Asia and no such studies from Latin 
America (appendix p 10). As studies were often done in 
high-risk communities, they might not be nationally 
representative, potentially yielding overestimates of non-
typhoidal salmonella invasive disease burden. Conversely, 
clinic-based surveillance would fail to capture individuals 
with non-typhoidal salmonella invasive disease who did 
not seek care. Although non-typhoidal salmonella 
invasive disease is generally regarded as a severe illness 
that would result in care-seeking, relatively mild or 
moderate forms of the disease might exist. Alternatively, 
given its rapid onset and high case fatality, some deaths 
from non-typhoidal salmonella invasive disease might 
occur before patients are able to reach health-care 
facilities, particularly for those living in remote areas 
who have to travel long distances to reach such facilities. 
To the extent that either mild or rapidly fatal cases occur, 
some proportion of non-typhoidal salmonella invasive 
disease cases might not present to health-care facilities, 
which would result in our model underestimating 
burden.
Our estimates of HIV PAFs have notably wide 
uncertainty, which reflects the scarce data available to 
inform this model: we found only six studies from 
four countries reporting RRs (or data allowing calculation 
of RRs), comparing the risk of non-typhoidal salmonella 
invasive disease among those with HIV to the risk among 
those without HIV (appendix p 56). Although increased 
use of antiretroviral therapy (ART) has been associated 
with decreasing non-typhoidal salmonella invasive 
disease incidence,23 we found insufficient data to allow us 
to account for effective ART in our HIV-attributable 
estimates. Accounting for the possible role of ART 
is complicated by evidence suggesting that the risk of 
bloodstream infections, including non-typhoidal salmo- 
nella invasive disease, might dramatically increase 
during the first year after initiating ART, and then decline 
below pre-ART levels in subsequent years.24,25 Our results 
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might, therefore, underestimate HIV-attributable propor- 
tions in the years before widespread ART use, and 
overestimate those proportions in recent years.
Improved access to ART in the past decade has 
probably helped to reduce the burden of non-typhoidal 
salmonella invasive disease among those living with 
HIV, and continued support of ART programmes is 
essential for sustained progress on this front. Still, our 
estimates suggest that most non-typhoidal salmonella 
invasive disease cases are not attributable to HIV 
YLDs YLLs DALYs
Number 
(thousands)
Rate 
(per millions)
Number 
(thousands)
Rate 
(per millions)
Number 
(thousands)
Rate 
(per millions)
Year
1990 1·75 
(1·00 to 2·74)
0·30 
(0·17 to 0·47)
2993·9 
(1626·4 to 5216·5)
500·6 
(273·0 to 867·2)
2995·6 
(1628·5 to 5218·6)
500·9 
(273·3 to 867·7)
1995 2·09 
(1·18 to 3·26)
0·35 
(0·20 to 0·53)
3422·3 
(1889·7 to 5936·7)
559·3 
(310·0 to 964·8)
3424·4 
(1892·1 to 5939·2)
559·6 
(310·2 to 965·3)
2000 2·64 
(1·51 to 4·07)
0·42 
(0·24 to 0·65)
4200·6 
(2321·8 to 7173·7)
676·0 
(373·4 to 1152·3)
4203·2 
(2324·4 to 7175·5)
676·4 
(373·8 to 1152·6)
2005 3·49 
(2·06 to 5·44)
0·54 
(0·32 to 0·85)
5325·6 
(3106·9 to 8722·7)
835·8 
(487·5 to 1370·6)
5329·0 
(3110·6 to 8726·4)
836·4 
(488·1 to 1371·3)
2010 3·16 
(1·81 to 5·03)
0·47 
(0·27 to 0·75)
4847·6 
(2743·8 to 8116·5)
731·8 
(415·1 to 1234·0)
4850·7 
(2745·7 to 8121·7)
732·3 
(415·4 to 1234·6)
2017 2·73 
(1·55 to 4·29)
0·38 
(0·22 to 0·61)
4260·8 
(2382·0 to 7378·6)
616·5 
(346·8 to 1075·8)
4263·5 
(2384·9 to 7382·0)
616·8 
(347·3 to 1076·2)
GBD super-region
Southeast Asia, 
east Asia, and 
Oceania
0·11 
(0·06 to 0·17)
0·06 
(0·04 to 0·10)
85·3 
(47·1 to 145·7)
49·8 
(27·4 to 87·5)
85·4 
(47·2 to 145·7)
49·9 
(27·4 to 87·6)
Central Europe, 
eastern Europe, 
and central Asia
0·02 
(0·01 to 0·04)
0·07 
(0·04 to 0·10)
17·0 
(9·1 to 29·4)
49·1 
(25·4 to 88·6)
17·0 
(9·2 to 29·4)
49·2 
(25·5 to 88·7)
High-income 0·06 
(0·03 to 0·08)
0·06 
(0·03 to 0·09)
22·1 
(11·0 to 39·5)
24·9 
(12·2 to 46·9)
22·2 
(11·0 to 39·6)
25·0 
(12·3 to 47·0)
Latin America and 
Caribbean
0·06 
(0·03 to 0·09)
0·10 
(0·06 to 0·16)
48·8 
(27·2 to 82·5)
89·5 
(50·5 to 150·4)
48·9 
(27·3 to 82·6)
89·6 
(50·6 to 150·6)
North Africa and 
Middle East
0·08 
(0·05 to 0·13)
0·13 
(0·08 to 0·20)
109·0 
(61·2 to 181·5)
175·1 
(98·4 to 289·7)
109·1 
(61·2 to 181·6)
175·2 
(98·5 to 289·8)
South Asia 0·25 
(0·14 to 0·39)
0·14 
(0·08 to 0·22)
286·2 
(154·2 to 488·0)
157·0 
(85·4 to 264·5)
286·5 
(154·4 to 488·3)
157·2 
(85·6 to 264·6)
Sub-Saharan Africa 2·15 
(1·17 to 3·55)
1·76 
(0·98 to 2·77)
3692·3 
(2040·5 to 6427·8)
2685·9 
(1493·7 to 4550·6)
3694·4 
(2042·7 to 6430·4)
2687·7 
(1495·4 to 4552·8)
Age group
<5 years 1·19 
(0·60 to 2·12)
1·74 
(0·88 to 3·12)
2685·5 
(1394·9 to 4872·0)
3945·6 
(2049·3 to 7158·0)
2686·7 
(1396·0 to 4873·0)
3947·3 
(2051·0 to 7159·3)
5–14 years 0·62 
(0·29 to 1·07)
0·48 
(0·22 to 0·83)
823·7 
(407·2 to 1485·1)
634·9 
(313·9 to 1144·6)
824·4 
(407·7 to 1486·2)
635·4 
(314·2 to 1145·4)
15–49 years 0·75 
(0·43 to 1·20)
0·19 
(0·11 to 0·31)
573·0 
(267·5 to 1037·9)
146·5 
(68·4 to 265·3)
573·7 
(268·1 to 1038·8)
146·7 
(68·5 to 265·6)
50–69 years 0·14 
(0·07 to 0·24)
0·10 
(0·05 to 0·18)
144·5 
(73·1 to 241·8)
109·6 
(55·5 to 183·4)
144·6 
(73·2 to 241·9)
109·7 
(55·5 to 183·5)
≥70 years 0·03 
(0·02 to 0·06)
0·08 
(0·04 to 0·13)
34·1 
(16·0 to 59·7)
78·7 
(37·0 to 137·9)
34·1 
(16·0 to 59·7)
78·8 
(37·0 to 138·0)
Sex
Male 1·42 
(0·80 to 2·25)
0·39 
(0·22 to 0·62)
2237·7 
(1234·8 to 3852·1)
629·6 
(348·8 to 1087·1)
2239·1 
(1236·3 to 3854·1)
630·0 
(349·3 to 1087·8)
Female 1·31 
(0·75 to 2·08)
0·38 
(0·21 to 0·60)
2,023·1 
(1146·5 to 3499·5)
602·9 
(339·8 to 1047·9)
2024·4 
(1147·6 to 3500·6)
603·3 
(340·0 to 1048·5)
95% uncertainty intervals are included in parentheses. Year-specific, age-specific, and sex-specific estimates are global estimates for 2017. Rates are age standardised, except 
for age-specific estimates. Estimates of YLLs and DALYs do not include burden for non-typhoidal salmonella invasive disease deaths attributable to HIV. YLD=years lived with 
disability. YLL=years of life lost. DALY=disability-adjusted life-year. GBD=Global Burden of Disease. 
Table 3: Years lived with disability, years of life lost, and disability-adjusted life-years from non-typhoidal salmonella invasive disease, by year, 
super-region, age, and sex
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infection, and reducing the burden of non-typhoidal 
salmonella invasive disease requires continued efforts to 
reduce acute malnutrition, prevent and treat malaria, 
improve access to safe water and sanitation, improve 
hygiene and food handling practices, and improve 
diagnostic techniques. Although better data and methods 
allowed us to improve upon previous estimates of non-
typhoidal salmonella invasive disease burden, data 
limitations remain a crucial challenge. Efforts to reduce 
the burden of non-typhoidal salmonella invasive disease 
will hinge on the quality of evidence driving decision 
making. More population-based studies from selected 
countries and regions, particularly in Latin America, are 
essential, as are studies on non-typhoidal salmonella 
invasive disease risk factors, including HIV, malaria, 
acute malnutrition, and sickle-cell disease.
Our results have important implications for clinical 
practice and public health policy. Given the high case 
fatality of non-typhoidal salmonella invasive disease, 
especially among elderly people and those living with HIV, 
clinicians in high-burden areas need to be aware of the 
scale of the problem and respond with timely 
and appropriate treatment. The paucity of data and 
uncertainties about the epidemiology of the disease 
highlight the urgent need for better screening and 
surveillance efforts to capture the true burden of non-
typhoidal salmonella invasive disease and to better inform 
policy makers. Despite these challenges, non-typhoidal 
salmonella invasive disease is clearly a major cause of death 
and disability that is likely to be responsible for a similar 
number of deaths and DALYs to salmonella enterocolitis. 
The inadequate attention paid to non-typhoidal salmonella 
invasive disease suggests that it remains an under-
recognised cause of global morbidity and mortality.
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